TrialThe Journal of clinical investigation2026

Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple-negative breast cancer CALGB 40603 (Alliance).

Patrick D Rädler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.